The Role of Luspatercept in the Evolving Treatment Landscape of LR-MDS
Thomas W. LeBlanc, MD, MA, discusses how erythroid maturation agents (EMAs), such as luspatercept, are increasingly important in the anemia management landscape for low-risk myelodysplastic syndromes (LR-MDS), with a focus on achieving hemoglobin levels ≥ 10, as highlighted by Santini et al in their ASH 2024 abstract, demonstrating the clinical significance of this target for improving patient outcomes.
Video Player is loading.
Video content above is prompted by the following:
- Where do you see EMAs in the landscape of anemia management in LR-MDS?
- What are your thoughts on hemoglobin levels ≥ 10?
Recent Videos
COMFORT Trials: Applying Evidence to Intermediate-Risk Myelofibrosis
Myelofibrosis Management: Clinical Approaches and Treatment Algorithms With Case-Based Application
Clinical Impact of COCOON: Advancing Dermatologic AE Management
Clinical Decision-Making Framework for Initiating Myelofibrosis Therapy
Clinical Approaches for Dermatologic AEs Associated With Amivantamab + Lazertinib in Advanced NSCLC
Prognostic Stratification on Myelofibrosis: From Models to Clinical Application
Ruxolitinib Therapy for cGVHD: Insights on Patient and Safety Monitoring
Personalized JAK Inhibitor Selection in Myelofibrosis: Clinical Characteristics, Molecular Profiles, and Treatment Sequencing
Advancing Treatment Paradigms in Myeloproliferative Neoplasms: From Molecular Pathogenesis to Patient-Tailored Therapy
Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease
Related Content
